These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 36822363)

  • 41. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer.
    Abbosh C; Hodgson D; Doherty GJ; Gale D; Black JRM; Horn L; Reis-Filho JS; Swanton C
    Trends Cancer; 2024 Jul; 10(7):643-654. PubMed ID: 38839544
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
    Loupakis F; Sharma S; Derouazi M; Murgioni S; Biason P; Rizzato MD; Rasola C; Renner D; Shchegrova S; Koyen Malashevich A; Malhotra M; Sethi H; Zimmermann BG; Aleshin A; Moshkevich S; Billings PR; Sedgwick JD; Schirripa M; Munari G; Cillo U; Pilati P; Dei Tos AP; Zagonel V; Lonardi S; Fassan M
    JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34327297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations.
    Andersson D; Kristiansson H; Kubista M; Ståhlberg A
    Expert Rev Mol Diagn; 2021 Mar; 21(3):299-310. PubMed ID: 33683971
    [No Abstract]   [Full Text] [Related]  

  • 46. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
    Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
    Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer.
    Xia J; Zhang J; Xiong Y; Zhao J; Zhou Y; Jiang T; Zhu J
    Expert Rev Mol Diagn; 2023; 23(10):913-924. PubMed ID: 37702546
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating tumour DNA, a promising biomarker for the management of colorectal cancer.
    Khakoo S; Georgiou A; Gerlinger M; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2018 Feb; 122():72-82. PubMed ID: 29458792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
    Bent A; Raghavan S; Dasari A; Kopetz S
    Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Precision Medicine for Advanced Solid Malignancies Based on Circulating Tumor DNA Analysis].
    Ishii T; Nakamura Y
    Gan To Kagaku Ryoho; 2020 Dec; 47(12):1645-1652. PubMed ID: 33342975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
    Abbosh C; Birkbak NJ; Swanton C
    Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.
    Chaudhuri AA; Chabon JJ; Lovejoy AF; Newman AM; Stehr H; Azad TD; Khodadoust MS; Esfahani MS; Liu CL; Zhou L; Scherer F; Kurtz DM; Say C; Carter JN; Merriott DJ; Dudley JC; Binkley MS; Modlin L; Padda SK; Gensheimer MF; West RB; Shrager JB; Neal JW; Wakelee HA; Loo BW; Alizadeh AA; Diehn M
    Cancer Discov; 2017 Dec; 7(12):1394-1403. PubMed ID: 28899864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.
    Yeung KT; More S; Woodward B; Velculescu V; Husain H
    Mol Diagn Ther; 2017 Aug; 21(4):375-384. PubMed ID: 28337711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
    Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
    J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.
    Cabalag CS; Yates M; Corrales MB; Yeh P; Wong SQ; Zhang BZ; Fujihara KM; Chong L; Hii MW; Dawson SJ; Phillips WA; Duong CP; Clemons NJ
    Ann Surg; 2022 Aug; 276(2):e120-e126. PubMed ID: 35737908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
    Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
    Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serial circulating tumor DNA profiling predicts tumor recurrence after liver transplantation for liver cancer.
    Huang A; Guo DZ; Zhang X; Sun Y; Zhang SY; Zhang X; Fu XT; Wang YP; Yang GH; Sun QM; He YF; Song K; Huang XW; Yang XR; Liu WR; Ding ZB; Shi YH; Fan J; Zhou J
    Hepatol Int; 2024 Feb; 18(1):254-264. PubMed ID: 37980313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
    Li FQ; Cui JW
    Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.
    Chen K; Shields MD; Chauhan PS; Ramirez RJ; Harris PK; Reimers MA; Zevallos JP; Davis AA; Pellini B; Chaudhuri AA
    Mol Diagn Ther; 2021 Nov; 25(6):757-774. PubMed ID: 34725800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.